WO2006021647A1 - Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin - Google Patents
Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin Download PDFInfo
- Publication number
- WO2006021647A1 WO2006021647A1 PCT/FR2005/001826 FR2005001826W WO2006021647A1 WO 2006021647 A1 WO2006021647 A1 WO 2006021647A1 FR 2005001826 W FR2005001826 W FR 2005001826W WO 2006021647 A1 WO2006021647 A1 WO 2006021647A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- fatty acid
- cis
- use according
- inflammatory reactions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to the use of a fatty acid for the preparation of a topical composition for the amelioration of inflammatory reactions due to the bites of Hymenoptera.
- Insects secreting substances that are harmful to humans are quite numerous in our regions. Among the wasps, hornets, bumble bees, ants and bees the risk of sting is not negligible. These insects are called hymenoptera. Their bite may cause local or general non-allergic reactions or local or generalized allergic reactions.
- Stings in the oral cavity and particularly at the back of the throat may cause respiratory problems through local edema.
- punctures in the eye, on the cornea can cause immediate complications such as ocular abscesses or perforations of the globe. Some complications may appear later: cataracts or glaucoma.
- Hymenoptera include many species including bees, wasps, hornets, ants. Although the majority of the bites of these hymenoptera cause only moderate pain and limited and temporary reaction, they can be dangerous or even fatal if they are multiple, if they occur in the mouth, throat, or at the level eyes, or if the stung subject triggers an allergic-type reaction.
- the stung person first feels more or less pain depending on the type of insect and the amount of venom injected. The skin around the sting becomes red and swollen. The subject feels itching more or less intense.
- insect venom and in particular bee venom is a complex substance comprising a large number of active compounds among which histamine, melittin, hyaluronidase and phospholipidase A.
- histamine, melittin, hyaluronidase and phospholipidase A histamine, melittin, hyaluronidase and phospholipidase A.
- the sensitivity to these venom proteins might explain some of the reactions outlined above.
- the Applicant has thus found, surprisingly, that these fatty acids, in particular those containing C12-C24, considerably reduce the inflammatory reaction which follows a bite of hymenopteran.
- the present invention relates to the use of a fatty acid for the preparation of a topical or injectable composition for the alleviation of inflammatory reactions due to the bites of Hymenoptera.
- the fatty acids used in the present invention are preferably natural fatty acids, that is to say that can be obtained from natural products such as oils, but also synthetic fatty acids that are identical or different from natural fatty acids. .
- the usable fatty acids may be saturated or unsaturated fatty acids. It is also conceivable to use the pharmaceutically acceptable salts or derivatives of these fatty acids which are included in the fatty acid designation.
- C12 to C24 acids Lauric acid (n-Dodecanoic acid), Myristic acid (n-Tetradecanoic acid), Palmitic acid (n-Hexadecanoic acid), Stearic acid (n - Octadecanoic), Arachidic (n-Eicosanoic), Behenic (n-Docosanoic), Lignoceric (n-Tetracosanoic), Palmitoleic (cis- ⁇ 9 -Hexadecenoic), Oleic (cis- ⁇ 9 -Octadecenoic), Linoleic (cis, cis - ⁇ 9 -, ⁇ 12 - Octadecadienoic), Linolenic (all-cis- ⁇ 9 -, ⁇ 12 -, ⁇ 15 -Octadecatrienoic), Arachidonic (all-cis- ⁇ 5 -
- Polyunsaturated fatty acids and linoleic and oleic acids are particularly active in the object of the invention.
- Fatty acids have been tested in vitro for their ability to inhibit the activity of some of the pro-inflammatory components of bee venom, and in vivo in rats in models of edema induced by bee venom. The results of these tests show that the fatty acids can be used for the manufacture of compositions intended for the local treatment of inflammations following the bites of venom hymenopterans.
- composition whose use is the subject of the invention may further comprise other active ingredients including anesthetic and / or an antibiotic and / or an anti-allergic or anti-inflammatory substance.
- the fatty acids may be formulated in any form suitable for topical administration, in combination with suitable excipients to allow administration of a dose of 0.01 to 50 mg per venom hymenopteran bite.
- the dose may of course vary depending on the amount of venom absorbed, the number of bites or the type of insect.
- galenic formulations that can be adapted for the implementation of the invention include ointments, creams, gels, patches, powders, sprays or lotions.
- An application with a stick can be particularly advantageous for single stings on a member for example. If the mucous membranes or the eyes are affected, a formulation in the form of a spray or eye drops is preferred.
- composition forming the subject of the present invention by local injection.
- active substances of the pharmaceutical compositions according to the invention may be dissolved or suspended in a pharmaceutically acceptable sterile injectable liquid, such as sterile water, a sterile organic solvent or a mixture of these two liquids for local administration, to allow administration of a dose of 0.001 to 1 mg per venom hymenopteran bite.
- a pharmaceutically acceptable sterile injectable liquid such as sterile water, a sterile organic solvent or a mixture of these two liquids for local administration, to allow administration of a dose of 0.001 to 1 mg per venom hymenopteran bite.
- Fig. 1 illustrates the percentage inhibition of PLA 2 activity of bee venom as a function of the acid concentration which is used for: 1.A - Linoleic acid (Example 1) 1.B - Acid oleic (example 1)
- Fig. 2 illustrates the effect of oleic and linoleic acid on the increase in the volume of the rat paw in an inflammation model, as a function of the time after injection of the bee venom (example 2 - experiment 1).
- Fig. 3 illustrates the effect of oleic and linoleic acid the increase in the volume of the rat paw in a model of inflammation, as a function of the time after injection of the bee venom (example 2 - experiment 2)
- Fig. 4 illustrates the effect of oleic and linoleic acid the increase in the volume of the rat paw in a model of inflammation, as a function of the time after injection of the bee venom (example 2 - experiment 3)
- Example I In vitro inhibitory effects of linoleic acid and oic acid on the activity of phospholipase A2 of bee venom (PLA2), a major inflammatory component of this venom:
- PLA2 activity is measured according to the hexane extraction method described by K ⁇ tsum ⁇ t ⁇ , M. Gupt ⁇ , G. and Goldman AS., (1986), Anal. Biochem. 154 (2), 676-681.
- PLA2 activity is determined using a radioactive substrate, La-dipalmitoyl- [2,9,10 (N) -3H-p-mitoyl] -phosphatidylcholine.
- the reaction is carried out in 1 ml of glycine / NaOH buffer, pH 9, containing 2.2 mM deoxycholate, 0.11 ⁇ Ci of dipalmitoyl-PC and 32 mU / ml PLA2 of bee venom. After 20 minutes of incubation, the reaction is stopped by adding 0.2 ml of a Triton X-100 / EDTA solution, then the reaction product, the radiolabelled palmityc acid, is extracted with a hexane solution containing 0.1% of acetic acid and 0.7g / ml of Na2SO4. The radioactivity of the extracts is determined using a liquid scintillation counter. The results represent the mean ⁇ SEM of the CPM values obtained in two independent experiments.
- FIGS. 1A and 1B illustrate the percentage inhibition of PLA2 activity (vertical axis) as a function of the concentration of fatty acid used (horizontal axis). These results demonstrate that linoleic and oleic acid inhibit in a dose-dependent manner the enzymatic activity of PLA2 of bee venom.
- Bee venom (20 ⁇ g / ml in NaCl 0.9%) is incubated at room temperature, in the presence or absence of linoleic acid (32 ⁇ M). 30 minutes after the start of the incubation, the solutions (25 ⁇ l) are injected subcutaneously to Sprague Dawley rats (110-140 g), at the level of the upper surface of the foot. Edema is measured with a plethysmometer 5 - 10 - 15 - 20 - 30 - 60 and 90 minutes after injection. The results represent the mean ⁇ SEM of 5 animals. Statistical comparisons are made by a t-test, of which the control group consists of animals that received venom alone. * P ⁇ 0.05, *** P ⁇ 0.005. The results are shown in Figure 2. Experience 2:
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005276345A AU2005276345A1 (en) | 2004-07-21 | 2005-07-18 | Use of a fatty acid for preparing a topical composition for allaying inflammatory reactions due to venemous hymenoptera stings |
US11/572,437 US20080096963A1 (en) | 2004-07-21 | 2005-07-18 | Use Of A Fatty Acid For Preparing A Topical Composition For Allaying Inflammatory Reaction Due To Vennemous Hymenoptera Strings |
EP05791091A EP1768659A1 (fr) | 2004-07-21 | 2005-07-18 | Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin |
CA002574345A CA2574345A1 (fr) | 2004-07-21 | 2005-07-18 | Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin |
IL180814A IL180814A0 (en) | 2004-07-21 | 2007-01-18 | Use of a fatty acid for preparing a topical composition for allaying inflammatory reactions due to venomous hymenoptera stings |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0408070A FR2873293B1 (fr) | 2004-07-21 | 2004-07-21 | Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin |
FR0408070 | 2004-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006021647A1 true WO2006021647A1 (fr) | 2006-03-02 |
Family
ID=34948226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/001826 WO2006021647A1 (fr) | 2004-07-21 | 2005-07-18 | Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin |
Country Status (7)
Country | Link |
---|---|
US (1) | US20080096963A1 (fr) |
EP (1) | EP1768659A1 (fr) |
AU (1) | AU2005276345A1 (fr) |
CA (1) | CA2574345A1 (fr) |
FR (1) | FR2873293B1 (fr) |
IL (1) | IL180814A0 (fr) |
WO (1) | WO2006021647A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20111284A1 (it) * | 2011-07-11 | 2013-01-12 | Giovanni Nusca | Composizione farmaceutica. |
US10232048B1 (en) | 2014-11-18 | 2019-03-19 | Divine Api-Logics, LLC | Apitherapy method and composition |
JP6734290B2 (ja) * | 2015-03-20 | 2020-08-05 | ダウ グローバル テクノロジーズ エルエルシー | 不飽和脂肪の酸化のニトロン抑制 |
EP3448378B1 (fr) | 2016-04-29 | 2024-04-17 | Ophirex, Inc. | Inhibiteurs de pla2 et hmg-coa pour le traitement des affections pathologiques provoquant une hémolyse, un oedème cérébral, et une insuffisance rénale aiguë |
TW202308606A (zh) | 2017-12-26 | 2023-03-01 | 福岡大太朗 | 飽和脂肪酸或其醫藥上可容許之鹽的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0993827A1 (fr) * | 1997-06-13 | 2000-04-19 | Taisho Pharmaceutical Co., Ltd | Aerosols |
EP1163905A1 (fr) * | 1998-11-30 | 2001-12-19 | Nof Corporation | Preparations pour la peau a usage externe |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1913631A (en) * | 1929-09-13 | 1933-06-13 | Graves George De Witt | Means and method of neutralizing insect and plant poisons |
US20040185115A1 (en) * | 2002-05-17 | 2004-09-23 | Maurine Pearson | Emu oil based methods and compositions for skin ailments |
-
2004
- 2004-07-21 FR FR0408070A patent/FR2873293B1/fr not_active Expired - Fee Related
-
2005
- 2005-07-18 EP EP05791091A patent/EP1768659A1/fr not_active Withdrawn
- 2005-07-18 AU AU2005276345A patent/AU2005276345A1/en not_active Abandoned
- 2005-07-18 WO PCT/FR2005/001826 patent/WO2006021647A1/fr active Application Filing
- 2005-07-18 US US11/572,437 patent/US20080096963A1/en not_active Abandoned
- 2005-07-18 CA CA002574345A patent/CA2574345A1/fr not_active Abandoned
-
2007
- 2007-01-18 IL IL180814A patent/IL180814A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0993827A1 (fr) * | 1997-06-13 | 2000-04-19 | Taisho Pharmaceutical Co., Ltd | Aerosols |
EP1163905A1 (fr) * | 1998-11-30 | 2001-12-19 | Nof Corporation | Preparations pour la peau a usage externe |
Also Published As
Publication number | Publication date |
---|---|
FR2873293B1 (fr) | 2006-11-17 |
AU2005276345A1 (en) | 2006-03-02 |
IL180814A0 (en) | 2007-07-04 |
CA2574345A1 (fr) | 2006-03-02 |
FR2873293A1 (fr) | 2006-01-27 |
US20080096963A1 (en) | 2008-04-24 |
EP1768659A1 (fr) | 2007-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2710054C (fr) | Extract d'huile d'un mollusque bivalve riche en n-acylethanolamides | |
CA2332616A1 (fr) | Compositions pharmaceutiques, hygieniques et/ou cosmetiques contenant del'eau de mer et leurs utilisations | |
JP2011502995A (ja) | アンドログラフィス・パニキュラータ抽出物 | |
EP1035846B1 (fr) | Agnim comme agents anti-inflammatoires dans les tissus superficiels des mammiferes | |
CA2395121C (fr) | Composition, notamment cosmetique ou dermatologique, contenant des oligosaccharides, son procede de preparation et un procede de traitement cosmetique | |
WO2006021647A1 (fr) | Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin | |
FR3045385A1 (fr) | Composition cosmetique comprenant des inhibiteurs de l'expression du facteur de croissance nerveuse (nerve growth factor) pour le traitement du psoriasis, de la dermatite atopique et du prurit | |
FR2885050A1 (fr) | Composition amincissante a base d'extraits de cacao. | |
US11446277B2 (en) | Penetrating pain relief cream | |
WO2007014379A2 (fr) | Extrait lipidique provenant de lepidium meynii et effet de celui-ci sur la libido | |
US20090202645A1 (en) | Intrasynovial formulations of stanozolol | |
FR3015292A1 (fr) | Composition a base d'omega 6 amide bourrache | |
CA1289884C (fr) | MEDICAMENT A ACTION SYNERGETIQUE ANTI-INFLAMMATOIRE A BASE D'UN CORTICOSTEROIDE ET D'UN .beta.-AGONISTE | |
EP1448208B1 (fr) | Composition a base d'ester de diosgenine applicable par voie topique | |
EP3675814A1 (fr) | Composition pour le traitement topique de maladies inflammatoires de la peau et des muqueuses non provoquées par des micro-organismes | |
FR2733418A1 (fr) | Nouvelles associations comprenant du (-) hydroxycitrate et presentant notamment de nouvelles activites therapeutiques | |
CA2065572C (fr) | Nouvelles compositions dietetiques a base de lipides complexes phosphores et leur utilisation dans les troubles du sommeil | |
EP1891940B1 (fr) | Formulations intrasynoviales de stanozolol | |
EP1523321B1 (fr) | Utilisation d'extraits de ginkgo biloba pour favoriser la masse musculaire au detriment de la masse graisseuse | |
EP0225833A2 (fr) | Composition destinée à être utilisée en médecine vétérinaire, en particulier pour le traitement des affections de l'appareil locomoteur ou pour la préparation à l'effort et la récupération par exemple chez le cheval de sport ou le chien de travail, notamment de chasse | |
EP1841459B1 (fr) | Utilisation d'un derive de dihydroimidazopyrazine pour traiter ou prevenir la douleur | |
FR2747307A1 (fr) | Application a titre de medicament des ceramides et compositions notamment pharmaceutiques les renfermant | |
FR2747308A1 (fr) | Association de margousier, de (-) hydroxycitrate et de ceramides et compositions les renfermant | |
FR2771005A1 (fr) | Nouvelle association pharmaceutique a activite analgesique | |
CA1117041A (fr) | Complexe lipoproteique normalisant l'efficacite de la vitamine e et des antioxydants de synthese |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 180814 Country of ref document: IL Ref document number: 2574345 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11572437 Country of ref document: US Ref document number: 2005276345 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005791091 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005276345 Country of ref document: AU Date of ref document: 20050718 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005276345 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005791091 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11572437 Country of ref document: US |